Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02194049
Recruitment Status : Completed
First Posted : July 18, 2014
Last Update Posted : January 9, 2018
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
This phase I trial studies the side effects and the best dose of PI3K inhibitor BKM120 when given together with cisplatin and etoposide in treating patients with advanced solid tumors or small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing , or by stopping them from spreading. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving PI3K inhibitor BKM120 with cisplatin and etoposide may kill more tumor cells.

Condition or disease Intervention/treatment Phase
Extensive Stage Small Cell Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific Drug: BKM120 Drug: cisplatin Drug: etoposide Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the safety and feasibility of combining BKM120 (PI3K inhibitor BKM120) with cisplatin and etoposide in advanced solid tumors, with emphasis on small cell lung cancer (SCLC).

SECONDARY OBJECTIVE:

I. To determine the MTD (maximally tolerated dose) of BKM120 in combination with cisplatin/etoposide.

II. To describe the dose limiting toxicities (DLT) and toxicity profile associated with BKM120 in combination with cisplatin/etoposide.

III. To determine the preliminary efficacy of BKM120 in combination with cisplatin/etoposide in an expanded cohort of patients with SCLC.

IV. To characterize the pharmacokinetic (PK) parameters of BKM120 in this combination.

V. To collect blood samples for future exploratory biomarker analysis.

OUTLINE: This is a dose-escalation study of PI3K inhibitor BKM120.

Patients receive PI3K Inhibitor BKM120 orally (PO) once daily (QD) on days 1-21, cisplatin intravenously (IV) over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of treatment, patients are followed for 30 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of Cisplatin and Etoposide Plus BKM120 in Advanced Solid Tumors, With an Emphasis on Small Cell Lung Cancer
Study Start Date : July 2014
Actual Primary Completion Date : April 2016
Actual Study Completion Date : June 2016


Arm Intervention/treatment
Experimental: BKM 120, cisplatin, etoposide
Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: BKM120
Given PO
Other Name: PI3K_Inhibitor_BKM120

Drug: cisplatin
Given IV
Other Names:
  • CACP
  • CDDP
  • CPDD
  • DDP

Drug: etoposide
Given IV
Other Names:
  • EPEG
  • VP-16
  • VP-16-213




Primary Outcome Measures :
  1. Incidence of adverse events of combining daily BKM120 with cisplatin and etoposide as graded by the National Cancer Institute (NC) CTCAE version 4.0 [ Time Frame: Up to 28 days post-treatment ]
    The toxicities observed at each dose level will be summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity, time of onset (i.e. course number), duration, and reversibility or outcome.


Secondary Outcome Measures :
  1. MTD defined as the highest dose tested in which fewer than 33% of patients experience DLT attributed to the study drugs when at least 6 patients were treated at that dose, as graded by NCI CTCAE version 4.0 [ Time Frame: 21 days ]
    The toxicities observed at each dose level will be summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity, time of onset (i.e. course number), duration, and reversibility or outcome.

  2. Response rate assessed by computed tomography (CT) scan based on Response Evaluation Criteria In Solid Tumors (RECIST) [ Time Frame: Up to 30 days ]
    Response rate among patients with measurable disease will be summarized by exact binomial confidence intervals

  3. Overall survival [ Time Frame: Up to 30 days ]
    Survival will be summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol. Median survival time will be estimated using standard life table methods.

  4. Time to progression (TTP) based on RECIST [ Time Frame: Up to 30 days ]
    TTP will be summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol. Median time to progression will be estimated using standard life table methods.

  5. Pharmacokinetic analysis [ Time Frame: Baseline, at 1, 2, 4, 6, and 24 hours of day 1 of course 1, baseline day 15 of course 1, and at 1 and 2 hours post-dose on day 1 of course 2 ]
    Pharmacokinetic analysis will use non-linear curve fitting methods to estimate the mean peak concentration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological or cytological proven advanced solid tumors
  • =< 3 chemotherapy regimens for metastatic disease; any number of prior targeted or biologic therapies is allowed; (in the expansion cohort, patients must be chemo naïve)
  • ECOG performance status =< 2
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
  • Platelets >= 100 x 10^9/L
  • Hemoglobin (Hb) > 9 g/dL
  • Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)
  • Magnesium >= the lower limit of normal
  • Potassium within normal limits for the institution
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal (ULN) if liver metastases are present)
  • Serum bilirubin within normal range (or =< 1.5 x ULN if liver metastases are present; or total bilirubin =< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)
  • Serum creatinine =< 1.5 x ULN or calculated clearance >= 60 mL/min
  • Serum albumin >= 3 g/dl
  • Serum amylase =< ULN
  • Serum lipase =< ULN
  • Fasting plasma glucose =< 120 mg/dL (6.7 mmol/L)
  • International normalized ratio (INR) =< 2
  • Ability to swallow pills
  • Negative serum pregnancy test

Exclusion Criteria:

  • Received prior treatment with a P13K inhibitor
  • Received > 300 mg/m^2 of cisplatin and/or for whom cisplatin would not be beneficial
  • Prior treatment with any investigational drug within the preceding 3 weeks
  • Known hypersensitivity to BKM120 or to its excipients
  • Untreated brain metastases are excluded
  • Acute or chronic liver, renal disease or pancreatitis
  • Following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient's mood assessment questionnaire
  • Diarrhea >= CTCAE grade 2
  • Active cardiac disease
  • History of cardiac dysfunction
  • Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus
  • Other concurrent severe and/or uncontrolled concomitant medical conditions
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with unresolved diarrhea will be excluded as previously indicated
  • Treated with any hematopoietic colony-stimulating growth factors
  • Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug
  • Chronic treatment with steroids or another immunosuppressive agent
  • Herbal medications and certain fruits within 7 days prior to starting study drug
  • Treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug
  • Intravenous chemotherapy or targeted anticancer therapy =< 4 weeks
  • Any continuous or intermittent oral small molecule therapeutics
  • Received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  • Undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  • Currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant
  • Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control
  • Known diagnosis of HIV infection
  • History of another active malignancy
  • Unable or unwilling to abide by the study protocol or cooperate fully with the investigator treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02194049


Locations
Layout table for location information
United States, California
University of California at Davis Cancer Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
Novartis
Investigators
Layout table for investigator information
Principal Investigator: Karen Kelly University of California, Davis
Layout table for additonal information
Responsible Party: University of California, Davis
ClinicalTrials.gov Identifier: NCT02194049    
Other Study ID Numbers: UCDCC#239
470970 ( Registry Identifier: UC Davis )
CBKM120ZUS38T ( Other Identifier: Novartis )
UCDCC#239 ( Other Identifier: University of California at Davis Cancer Center )
NCI-2014-00218 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: July 18, 2014    Key Record Dates
Last Update Posted: January 9, 2018
Last Verified: June 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Etoposide
Etoposide phosphate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action